Similar real‐world two‐year visual acuity gains in treatment‐naive patients with diabetic macular oedema treated with a loading dose of three initial monthly injections versus less intensive regimens of intravitreal anti‐vascular endothelial growth factor. Issue 7 (6th May 2021)